BioTime, Inc. (BTX) Analysts See $-0.06 EPS

February 15, 2018 - By Louis Casey

 BioTime, Inc. (BTX) Analysts See $ 0.06 EPS
Investors sentiment decreased to 1.96 in 2017 Q3. Its down 0.17, from 2.13 in 2017Q2. It fall, as 9 investors sold BioTime, Inc. shares while 15 reduced holdings. 9 funds opened positions while 38 raised stakes. 49.13 million shares or 2.79% more from 47.80 million shares in 2017Q2 were reported.
Huntington Bancshares holds 0% or 200 shares in its portfolio. Moreover, Prescott General Ptnrs Lc has 0.27% invested in BioTime, Inc. (NYSEAMERICAN:BTX) for 1.85M shares. Iowa National Bank reported 10,000 shares. 867,613 are owned by Northern Tru. Swiss National Bank & Trust stated it has 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX). Comml Bank Of Montreal Can holds 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX) for 3,350 shares. Bnp Paribas Arbitrage reported 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX). Jacobs Levy Equity Mgmt Inc holds 0.01% or 141,752 shares in its portfolio. Moreover, Fifth Third National Bank & Trust has 0% invested in BioTime, Inc. (NYSEAMERICAN:BTX) for 4,200 shares. Sg Americas Secs Limited Company holds 0% of its portfolio in BioTime, Inc. (NYSEAMERICAN:BTX) for 12,401 shares. Carl Domino stated it has 37,000 shares. 11,800 were reported by Gluskin Sheff & Associates Inc. Intll Inc reported 0% stake. California Pub Employees Retirement holds 0% or 48,400 shares. California State Teachers Retirement holds 119,139 shares.

Since October 13, 2017, it had 1 buy, and 0 sales for $7.00 million activity.

Analysts expect BioTime, Inc. (NYSEAMERICAN:BTX) to report $-0.06 EPS on March, 15.After having $-0.05 EPS previously, BioTime, Inc.’s analysts see 20.00 % EPS growth. The stock decreased 1.13% or $0.03 during the last trading session, reaching $2.62. About 218,590 shares traded. BioTime, Inc. (NYSEAMERICAN:BTX) has risen 22.71% since February 15, 2017 and is uptrending. It has outperformed by 6.01% the S&P500.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $332.39 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It has a 6.09 P/E ratio. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

More recent BioTime, Inc. (NYSEAMERICAN:BTX) news were published by: Businesswire.com which released: “BioTime to Participate at the BIO CEO and Investor Conference in New York …” on February 07, 2018. Also Businesswire.com published the news titled: “Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference” on January 29, 2018. Businesswire.com‘s news article titled: “and Vision Restoration Programs to Be Presented at ARVO 2018” with publication date: February 15, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: